Europeiska unionen - svenska - EMA (European Medicines Agency)

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiska medel - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

zentiva k.s. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

tillomed pharma gmbh - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ever valinject gmbh - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukemi, myeloid, akut - antineoplastiska medel - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - mannitol hjälpämne; azacitidin 25 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios lorien s.l. - azacitidin - pulver till injektionsvätska, suspension - 25 mg/ml - azacitidin 25 mg aktiv substans; mannitol hjälpämne